Werewolf Therapeutics (HOWL) vs Rafael (RFL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Werewolf Therapeutics (HOWL) has outperformed Rafael (RFL) over the past year, gaining 8.4% versus a loss of 25.8%. Over five years, RFL leads with a -84.2% price change compared with -93.7% for HOWL. Rafael is the larger company by market cap ($48.0 million vs $46.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HOWL | RFL |
|---|---|---|
| Share price | $0.9466 | $0.9197 |
| Market cap | $46.00M | $47.99M |
| 1-day change | -3.97% | +2.19% |
| YTD return | +49.31% | -22.06% |
| 1-year return | +8.43% | -25.83% |
| 5-year return | -93.68% | -84.19% |
| EPS (TTM) | $-0.58 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $874.00K |
| Revenue growth (YoY) | — | -4.69% |
| Net income (latest FY) | $-60.82M | $-29.64M |
| Operating margin | — | -3822.54% |
| Net margin | — | -3390.73% |
| 52-week high | $1.20 | $3.96 |
| 52-week low | $0.27 | $0.781 |
| Distance from 52-week high | -21.12% | -76.78% |
| Analyst consensus | none | — |
| Avg. price target upside | +639.49% | — |
| Average volume | 1.08M | 140.84K |
| Shares outstanding | 48.60M | 51.39M |
| Employees | 39 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HOWL has outperformed RFL by 34.3 percentage points over the past year.
About Werewolf Therapeutics
HOWL stock →Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
About Rafael
RFL stock →Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
HOWL vs RFL FAQ
Which is bigger, Werewolf Therapeutics or Rafael?
Rafael (RFL) is larger, with a market capitalization of $47.99M compared with $46.00M for Werewolf Therapeutics (HOWL).
Which stock has performed better over the past year, HOWL or RFL?
HOWL returned +8.43% over the past 12 months, compared with -25.83% for RFL (price return, excluding dividends). Past performance does not predict future results.
Are Werewolf Therapeutics and Rafael in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.